Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

UL Solutions' $350M Worldly Deal Shows Data and Compliance Assets Joining the Dealmaking Mix

UL Solutions' purchase of Worldly, holder of exclusive Higg Index marketing rights, sits outside pharma but echoes a week of small-cap consolidation and capability-led deals in the sector.

17 Nov 2026 · CompePharma editorial

What happened

UL Solutions has agreed to acquire Worldly Holdings in a deal of roughly $350M. Worldly is a supply chain software company and holds exclusive marketing rights to the Higg Index. The testing and certification group will also repurchase $130M of Class B shares. The material does not say how that repurchase relates to the $350M headline figure, whether it is included or additional, so readers should wait for the deal documents before comparing the numbers.

The deal is not a pharmaceutical transaction, and CompePharma's readers should treat it as a read-across rather than a sector event. Its interest is in what the buyer is paying for: a software platform and a controlled index, not a product or a plant.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →